A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other than Candida krusei in adults without neutropenia. A total of 219 patients met criteria for a modified intent-to-treat analysis. The groups were similar except that those who were treated with fluconazole plus placebo had a higher mean ‫ע(‬ standard error) Acute Physiology and Chronic Health Evaluation II score ( vs. ; ). Success rates on 16.8 ‫ע‬ 0.6 15.0 ‫ע‬ 0.7 P p .039 study day 30 by Kaplan-Meier time-to-failure analysis were 57% for fluconazole plus placebo and 69% for fluconazole plus AmB ( ). Overall success rates were 56% (60 of 107 patients) and 69% (77 of 112 P p .08 patients; ), respectively; the bloodstream infection failed to clear in 17% and 6% of subjects, respec-P p .043 tively ( ). In nonneutropenic subjects, the combination of fluconazole plus AmB was not antagonistic P p .02 compared with fluconazole alone, and the combination trended toward improved success and more-rapid clearance from the bloodstream.
A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other than Candida krusei in adults without neutropenia. A total of 219 patients met criteria for a modified intent-to-treat analysis. The groups were similar except that those who were treated with fluconazole plus placebo had a higher mean ‫ע(‬ standard error) Acute Physiology and Chronic Health Evaluation II score ( vs. ; ). Success rates on 16.8 ‫ע‬ 0. 6 15.0 ‫ע‬ 0.7 P p .039 study day 30 by Kaplan-Meier time-to-failure analysis were 57% for fluconazole plus placebo and 69% for fluconazole plus AmB ( ). Overall success rates were 56% (60 of 107 patients) and 69% (77 of 112 P p .08 patients;
), respectively; the bloodstream infection failed to clear in 17% and 6% of subjects, respec-P p .043 tively ( ). In nonneutropenic subjects, the combination of fluconazole plus AmB was not antagonistic P p .02 compared with fluconazole alone, and the combination trended toward improved success and more-rapid clearance from the bloodstream.
Available drugs for therapy of invasive candidiasis are limited, as are data on their best use. Amphotericin B (AmB) and fluconazole have produced similar results in large prospective [1, 2] and observational [3, 4] stud-ies. However, rates of persistent candidemia of 12%-14% [1, 2, 4] for both drugs in addition to concerns about the possible need for higher doses of fluconazole and AmB for selected non-albicans species of Candida [5] suggest a need for alternative strategies. In particular, pharmacokinetic analyses suggest that a dosage of 800 mg per day (∼12 mg/kg) would be more likely to be successful against isolates with MICs approaching the interpretive breakpoint for fluconazole resistance than would the currently recommended dosage of 400 mg per day (∼6 mg/kg) [6, 7] .
Another approach to improving response rates is to combine agents. Combination therapy is used for bacterial infections, but combinations of azole antifungal agents plus AmB have been approached cautiously as a result of the potential for antagonism between these 2 drug classes [8] . However, the combination of fluconazole and AmB for candidal infections in a murine model suggested that simultaneous initiation of therapy with both agents produced an additive effect [9] . In a previous study, we compared fluconazole at 400 mg per day with AmB at 0.5-0.6 mg/kg per day [1] . By use of an essentially identical study design, we have now examined the safety and efficacy of fluconazole at 800 mg per day with and without simultaneous AmB at 0.6-0.7 mg/kg per day as therapy for candidemia.
METHODS

Study design.
The study (National Institute of Allergy and Infectious Diseases Mycoses Study Group [NIAID-MSG] Study 33) was reviewed by the institutional review boards of all participating centers. Appropriate written informed consent was obtained from all study participants, and all applicable guidelines for human experimentation were followed. The Data and Safety Monitoring Board of the NIAID-MSG monitored the study.
Enrollment. Eligible subjects were у13 years old, had у1 blood culture positive for Candida species р4 days before study entry, and demonstrated у1 of the following characteristics р48 h before study entry: a temperature of 137.8ЊC on 2 occasions 14 h apart, a temperature 138.6ЊC on 1 occasion, a systolic blood pressure of !90 mm Hg, a decrease in the systolic blood pressure of у30 mm Hg from the baseline value, or signs of inflammation (swelling, heat, erythema, or purulent drainage) from a site infected with Candida species.
Patients were excluded from the study if they had neutropenia (absolute neutrophil count, !500 neutrophils/mm 3 ); were expected to become neutropenic during therapy; had a history of intolerance or allergy to azole antifungal agents or AmB; had serum levels of aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase of 110 times the upper limit of normal (ULN); had total serum bilirubin levels of 18 mg/dL (136.8 mM); had a prothrombin time 15 s greater than the control value or the ULN that was not correctable with vitamin K; were female and were pregnant, lactating, or unwilling to use adequate birth control measures for the duration of the study; were thought unlikely to survive for 124 h; had received AmB (10.7 mg/kg), fluconazole (800 mg), or an investigational drug р14 days before study entry; had experienced treatment failure with previous systemic antifungal therapy for the candidal infection being studied; had previously participated in this study; were receiving or were to receive any other systemic antifungal drug during the course of the study; were infected or found to be infected with Candida krusei; or were receiving terfenadine.
Randomization and administration of study drugs. After enrollment, each patient was assigned to an organ transplantation or non-organ transplantation stratum. Patients were randomized within these strata in a 1:1 ratio to receive fluconazole plus placebo (FP) or fluconazole plus AmB deoxycholate (FA) on the basis of a sequential list of block-randomized assignments maintained by each participating institution's pharmacy. For both study arms, fluconazole (800 mg) was administered intravenously daily for the first 5 days and then orally, unless the patient's condition precluded reliable oral therapy. If the patient weighed !50 kg or 190 kg, the dosage of fluconazole was the multiple of 50 closest to 12 mg/kg. The dose of fluconazole was decreased by 50% in subjects with an estimated creatinine clearance !50 mL/min.
Patients were treated with the fluconazole component of the study regimen for у14 days after resolution of clinical findings related to the episode of candidemia or у14 days after the last positive deep-site (normally sterile) culture result occurred, whichever was longer. The placebo or AmB component was, by protocol, to be provided for the first 5-8 days of therapy. The assignment to placebo or AmB was blinded to all participants except each site's pharmacist. Patients assigned to receive AmB were provided 0.6-0.7 mg/kg per day with the goal of administering a total dose of у3 mg/kg. Patients assigned to receive placebo were provided an identically colored volume of multivitamin solution in dextrose. Concomitant ordering of hydrocortisone (up to 50 mg per day) or heparin (up to 1000 U per bag) to be added to the AmB/placebo infusion was permitted, but these drugs were only actually added to the infusion if the patient was receiving AmB. Regardless of study assignment, all subjects were to be medicated with diphenhydramine, acetaminophen, and/or ibuprofen before each AmB or placebo infusion.
Study therapy was discontinued if the patient's infection was unresponsive after у5 days or if there were marked adverse effects on the liver (alkaline phosphatase level of 1.5-fold more than the ULN or the baseline value, aspartate or alanine aminotransferase level of 3-fold more than the ULN or the baseline value, or total bilirubin level of 3-fold more than the ULN or the baseline value). If the serum creatinine level increased to 13.5 mg/dL (309 mM), the investigator was to alter the timing and amount of AmB-placebo therapy. Modification could in- Modified intent-to-treat population 107 112
NOTE. AmB, amphotericin B. a These 2 subjects were administratively removed from the study shortly after enrollment because the study drug available at the study center expired. b Four subjects in each treatment group never had a blood culture positive for Candida species. The remainder did not have a positive blood culture result within 4 days before study entry.
clude either temporary or permanent cessation of AmB-placebo therapy. In the event of early discontinuation of any component of the study regimen, treatment was scored as a failure only if additional systemic antifungal therapy was subsequently administered. Patients were observed for 12 weeks after cessation of study therapy. Analysis. Case-report forms were scored without knowledge of treatment assignment by 4 of the study investigators. Treatment was considered to be successful if all signs and symptoms thought by the local investigator to be due to the Candida infection resolved, if the results of cultures of blood samples obtained at end of therapy and during follow-up were negative, if the results of cultures of samples of normally sterile sites previously positive for Candida became negative, and if associated signs of local inflammation resolved. Treatment was considered to have failed if there was unresponsive infection (e.g., persistent fungemia or unimproved or progressive signs of sepsis) after у5 days of therapy, if unacceptable side effects necessitated a change in antifungal therapy, or if a patient withdrew from the study before improvement or failure had been clearly documented. Results considered to be successes at the end of therapy were reclassified as relapses if there was a blood culture positive for Candida species, if a visceral Candida infection was discovered, or if systemic antifungal therapy was provided during follow-up. For 12 subjects (7 provided with FP and 5 provided with FA), late use of antifungal therapy was deliberately ignored during the blinded review by the scoring investigators in selected cases in which the patient's fever had resolved and the patient had clearly otherwise responded: 3 of the subjects required long-term prophylaxis, and 9 were judged to have received either trivial or unnecessary therapy. For these 12 subjects, therapy was judged to have been successful, and study follow-up was censored at the point of initiation of late antifungal therapy.
The primary analysis was of time to failure in a modified intent-to-treat population (all randomized subjects who received у1 dose of study medication and for whom culture of a blood sample obtained within 4 days of study entry positive for a Candida species, except C. krusei). The day of failure was defined as the day that an alternative antifungal regimen was initiated, the day of death (if no alternative antifungal therapy was provided), or the last day of study therapy (if the patient withdrew from the study or developed toxicity without receiving alternative antifungal therapy). Time to failure was described by the Kaplan-Meier method and compared using the log-rank test. The Cochran-Mantel-Haenszel x 2 test, stratified by site, was used to compare the proportion of treatment failures.
The study was designed to detect a decrease in the cumulative proportion of treatment failures during the entire study observation period from 25% for FP to 10% for FA. Assuming that time to failure was exponentially distributed, that the accrual period was 2 years, and that the cumulative dropout rate was 30%, a sample size of 100 subjects per treatment group was sufficient to detect the 15% difference in cumulative proportion of failures at the 2-sided .05 significance level with power of 0.94 [10] . This sample size was also sufficient to detect a 15% difference between the 2 treatment groups with respect to the proportion of failures by a x 2 test at the 2-sided .05 significance level with power of 0.80 [11] .
Interim analyses of efficacy and safety were presented to the Data and Safety Monitoring Board after 50 and 97 subjects had been observed to the primary efficacy end point. The Lan-DeMets procedure with the O'Brien-Fleming stopping rule was used [12, 13] . The study was not stopped on the basis of the results of interim analyses. To maintain an overall .05 significance level after the 2 interim analyses, the level of significance for the final analysis is .0455. Values are shown as . mean ‫ע‬ SE
RESULTS
Enrollment and baseline characteristics of the subjects. From July 1995 through April 1999, 236 subjects were enrolled at 27 centers (table 1). The subjects in the study groups were similar at baseline (table 2) except for a slightly lower APACHE II score [14] in the FA group. Because only 5 organ transplantation stratum subjects were enrolled, analyses were not stratified by this factor.
Microbiology. Candida albicans was the most common species isolated (table 3). The first positive blood culture was obtained days before study enrollment in both treat-2.5 ‫ע‬ 0.1 ment groups. The blood culture result was still positive on or after the day of study enrollment for 53% of subjects.
Peripheral venipuncture was the source for у1 positive blood culture for 63.9% of subjects, all samples from positive blood Toxicity. Onset of renal dysfunction led to reduction in the study drug dosage in 3% and 23% ( ) but was the P ! .001 primary cause of study failure in only 5% and 3% ( ) of P 1 .5 subjects treated with FP and FA, respectively. Elevations in hepatic enzyme levels were observed in 9% of FP-treated subjects and 8% of FA-treated subjects, and they were the primary cause of study failure in 5% of each group. One FA-treated patient was withdrawn from the study when anaphylaxis occurred during study drug infusion.
Outcome. The treatment groups did not differ in the timeto-failure analysis ( figure 1) . In a secondary analysis of the proportion of subjects treated successfully, 60 (56%) of 107 FP-treated subjects and 77 (69%) of 112 FA-treated subjects had successful outcomes ( ). Success by species was the P p .043 same in each arm (table 3) . Causes of failure and relapse were also similarly distributed among the species and between study regimens, with the exception of failure of infection to clear the bloodstream, which was more common in the FP group (17%) than the FA group (6%; ; table 3). P p .02 Stepwise logistic regression was used to assess the statistical strength of the association between the proportion of failures and selected baseline covariates, and to evaluate the treatment effect adjusting for all other important covariates. The baseline covariates included (1) baseline APACHE II total score, (2) infecting species at baseline, (3) history of systemic antifungal treatment received before study entry, (4) catheter exchange by the start of study medication, (5) blood culture status on the day of initiation of study therapy, and (6) the history of risk factors for candidemia before study entry (table 2) . This analysis found that the odds of failure were increased by APACHE II score (OR, 1.09 per point; 95% CI, 1.03-1.14;
), by P p .001 the presence of a positive blood culture on the day of initiation of study therapy (OR, 2.73; 95% CI, 1.46-5.19; ), and P p .002 by prior hyperalimentation (OR, 2.26; 95% CI, 1.20-4.32;
). Odds of failure were decreased by infection with P p .013 Candida parapsilosis (OR, 0.18; 95% CI, 0.04-0.60; ) P p .011 NOTE. Values shown in the first row are numbers of subjects with у1 blood culture positive for a given species. The distribution of species did not differ between treatment groups ( , by x 2 test). The cases P 1 .5 of fungemia involving mixed pathogens in the fluconazole plus placebo (FP) treatment arm involved C. albicans and C. glabrata (3 subjects) and C. glabrata and C. parapsilosis (1 patient). In the fluconazole plus amphotericin B deoxycholate (FA) treatment arm, they involved C. albicans and C. glabrata (1 patient), C. albicans and C. parapsilosis (2 subjects), C. albicans and C. tropicalis (1 patient), C. glabrata and C. parapsilosis (1 patient), and C. glabrata and C. tropicalis (1 patient). The comparisons between study regimens are not significant for any individual species. However, the comparison of failure to clear the bloodstream is significant for all species taken together ( ). P p .02 a A patient infected with C. albicans and C. glabrata is counted twice. b A patient infected with both C. parapsilosis and C. glabrata is counted twice. This patient had persistence of both organisms and also had a C. krusei superinfection at the time study therapy was stopped. c A patient infected with C. albicans and C. parapsilosis is counted twice. d A patient infected with C. tropicalis and C. glabrata is counted twice. Figure 1 . The proportion of subjects still successfully treated for the first 30 days of the study, by Kaplan-Meier analysis of time to failure. By the log-rank test, the 2 curves do not differ ( ). Success rates P p .08 at 30 days were 57% for the fluconazole plus placebo group and 69% for the fluconazole plus amphotericin B group.
and by receipt of therapy with FA (OR, 0.62; 95% CI, 0.33-1.15;
). Thus, therapy with FA is associated with a 38% P p .128 lower odds of failure, even after adjustment for APACHE II score and the other factors found to be independently predictive by logistic regression.
As an alternative way to assess the effect of the APACHE II score, a stratified analysis of the relationship between the APACHE II score and outcome is shown in figure 2 . Although limited by the smaller numbers of subjects with the highest and lowest APACHE II scores, 2 features are evident. First, and similar to other data [3] , the response rate decreases as the APACHE II score increases, thus explaining the importance of the APACHE II score in the logistic regression analysis. Second, the response rates for the 2 treatment arms overlap at the lowest and highest APACHE II scores, but, overall, the FA treatment arm is consistently favored throughout the midrange of APACHE II scores.
Antagonism related to prestudy therapy with fluconazole was not noted. Of the FA-treated subjects, success was seen in 28 (70%) of 40 subjects who had received no prestudy antifungal therapy and in 37 (67%) of 55 subjects who had received у1 dose of prestudy fluconazole as their only prestudy antifungal therapy. The comparable results of success for FP-treated subjects were 62% (29 of 47 subjects who did not receive prior therapy) and 55% (27 of 49 subjects provided with fluconazole before study entry).
Death within 90 days of starting study therapy occurred for 42 (39%) of 107 FP-treated subjects and 45 (40%) of 112 FAtreated subjects. In a post hoc analysis in which subjects dying within 14 days after the end of therapy were considered to have had treatment failure, success rates of 50% were seen in both study arms.
Management of intravascular catheters. Eighty-two FPtreated subjects and 93 FA-treated subjects had a vascular catheter in place at the time of the first positive blood culture result and had complete catheter management data available for analysis. Catheters were removed and re-placed at a new site (no guide wire exchanges) on a single day on or before the first day of study therapy in 45 (55%) and 58 (62%) of these subjects, respectively ( ). This type of catheter exchange P p .36 reduced the mean time to clearance of the organism from the bloodstream by 1 day ( for the study as a whole. A P p .081) similar trend was seen for each study arm, but this did not attain statistical significance. Although catheter exchange was not randomized, and although this result may thus be confounded by other factors, the APACHE II scores (‫ע‬SE) were similar for the groups that did ( ) and did not 15.3 ‫ע‬ 0.7 ( ; ) undergo such an exchange. 15.9 ‫ע‬ 0.7 P p .608
DISCUSSION
We studied a large group of nonneutropenic subjects with candidemia and found that simultaneous administration of combined fluconazole and AmB therapy trended toward better overall success than fluconazole alone. This trend (P p .08) was evident in the primary analysis of time to failure and became statistically significant ( ) in the secondary analy-P p .043 sis of proportion of failure. Because the combination therapy group had a slightly lower baseline APACHE II score, treatment was also evaluated after adjustment by logistic regression. Although not statistically significant, combination therapy remained associated with 38% lower odds of failure even after adjustment for APACHE II score and the other factors shown to be relevant by logistic regression. In an analysis by APACHE II score, the advantage of combination therapy was evident across a range of APACHE II scores, but the difference between the arms was least for those with the lowest and highest APACHE II scores.
The 37% overall failure rate in this study is higher than the 26% rate in the prior NIAID-MSG study of candidemia [1] . Frequencies of the causes of failure are similar between the studies except for a 6% increase in early withdrawal and a 6% increase in discontinuation for toxicity in the current study. This total of a 12% difference in occurrence of both of these forms of failure was evenly distributed across the 2 study arms. This difference may be a reflection of the greater availability of alternative antifungal therapy and greater reluctance of physicians to tolerate toxicity. The rate of renal dysfunction in the FA arm of this study (24%) was similar to that of AmB alone (37%) in our prior study [1] . Likewise, the rate of increased hepatic enzymes for all subjects in this study (8%-9%) was similar to that of fluconazole alone at 400 mg per day (14%) in our prior study [1] .
It is of significant interest that the principal cause of the 13% for subjects with the same APACHE II score ‫5ע‬ points (e.g., the leftmost point of each line is the success rate for subjects having an APACHE II of , or 6 ‫ע‬ 5 1-11). The cell width of ‫5ע‬ for this rolling stratified analysis was chosen because it placed у10 subjects into each cell. Qualitatively similar results were obtained for cell widths of ‫3ע‬ and ‫.4ע‬ difference in success rates between the 2 study arms was an 11% difference in the rate of failure to clear the bloodstream. The 6% rate of persistent candidemia for FA treatment was lower than the rates of 15%, 16%, and 10% for fluconazole alone and 12%, 10%, and 14% for AmB alone in prior studies by Rex et al. [1] , Phillips et al. [2] , and Nguyen et al. [4] , respectively.
Of importance, there was no evidence of microbiological antagonism noted in the FA treatment arm, regardless of whether the subjects had previously received fluconazole. Given the conflicting results obtained in preclinical in vitro and in vivo studies of this combination for candidiasis [8] , this demonstration of lack of antagonism in humans is valuable.
The implications of this study for medical practice are limited by the failure of randomization to uniformly distribute the APACHE II scores. Although the logistic regression and the stratified analysis suggest that the combination arm does have a microbiological advantage, the most conservative conclusion is simply that combination therapy is no worse than fluconazole monotherapy across a range of species and patient conditions. On the other hand, combination therapy as initial treatment could be used to exploit the trend toward microbiological and thus clinical advantage of the combination at the cost of relatively mild toxicity. The combination would be especially suitable in settings where high local rates of species intrinsically resistant to both fluconazole (e.g., C. krusei or azole-resistant strains of other species) and AmB (Candida lusitaniae) suggest the need for empirical therapy with the broadest possible spectrum of action. Once the infecting species is known and the blood cultures have begun to clear, one agent or the other could be discontinued.
Conversely, the observation that combination therapy had the least advantage in very mild and very severe disease supports the common-sense notion that some patients have disease that is either so mild (i.e., a low APACHE II score) or so severe (i.e., a high APACHE II score) that the more-intensive combination therapy is unable to alter outcome meaningfully. For the stable patient with a low APACHE II score, these results are thus entirely consistent with prior data [1] and consensus recommendations [5, 15] that fluconazole is a suitable therapy for many episodes of candidemia. Despite its theoretical pharmacodynamic advantage, the 800 mg per day dosage of fluconazole used in study did not produce a result that was clearly superior to that seen in our prior study of 400 mg per day [1] , but comparisons are confounded by both the predominance in this study (as in all studies of candidemia) of isolates of species that are uniformly quite susceptible to fluconazole and the inherent potential for differences between sequentially performed studies. Our knowledge of the best management option for patients with a high severity of illness remains limited, and the overall outcome for these patients is poor.
In summary, combined therapy with fluconazole plus AmB was not antagonistic compared with fluconazole monotherapy and trended strongly toward improved success, albeit with greater associated nephrotoxicity and without an effect on mortality. Fluconazole at 800 mg per day was well tolerated. Clearance of the bloodstream was improved by removal of all vascular catheters on a single day without exchange over a guidewire from a preexisting site.
